Posts about:
Mental Health | In hospitalized children with autism spectrum disorder (ASD), predictors of co-morbid attention-deficit/hyperactivity disorder (ADHD)....
The combined results of 61 studies conducted in 19 countries suggest that when a woman gives birth by cesarean section, autism in the child is 33% more likely and the odds of attention-deficit/hyperactivity disorder (ADHD) increase by 17%.
How might an anti-cancer drug help to treat the symptoms of autism?
NeuroPointDX announced the availability of the NPDX AA test, the first objective blood test that identifies metabolic subtypes associated with autism spectrum disorder in children as young as 18 months old.
The NPDX AA test works by detecting amine imbalances in a child's fasting blood sample with very precise thresholds that were identified and validated based on samples from the Children's Autism Metabolome Project (CAMP) study (N=1100) in patients aged 18 to 48 months.
The metabolic imbalances, which were seen in ~30% of children with ASD, are not currently identified by other tests on the market. The test also provides metabolic information that may help clinicians determine optimal treatment strategies for patients with ASD.
Testing is recommended for children who have failed screening for developmental milestones indicating risk for ASD (eg, M-CHAT, ASQ-3, PEDS, STAT, etc.), who have a family history such as a sibling diagnosed with ASD, or for those who have been diagnosed with ASD and want additional metabolic information to provide insight into the condition and therapy.
Results are provided within 2 weeks; a positive test result should be further evaluated by a neurodevelopmental specialist.
“We are continuing to mine data from the CAMP study to identify and validate additional metabolic subtypes in children with ASD,” said Bob Burrier, Chief Operating Officer and Vice President of Research & Development at NeuroPointDX.
“Our aim is to further build on the utility of this test to identify a greater percentage of children with additional metabolic subtypes. The metabolic biomarkers we have identified will serve as targets for new therapies ranging from pharmaceuticals to dietary supplements, bringing precision medicine to the diagnosis and treatment of this neurodevelopmental disorder.” NeuroPointDx plans to launch a second test panel to market in 2019.
The NPDX AA test is available on a limited basis through the Company's early access program and must be ordered by a physician. The test is currently not covered by insurance.
Mental Health Minnesota | By taking folic acid around the time of conception, mothers-to-be may reduce their child's risk of pesticide-related autism.
It's estimated that one in 68 U.S. children has an autism spectrum disorder, which can range from mild to severe.
There is no single cause, but research suggests a combination of genetic and environmental influences plays a role, according to the U.S. National Institutes of Health.
Decades ago, autism spectrum disorder (ASD), a group of developmental disabilities in which patients have significant social, communication, and behavioral difficulties, was considered rare, and the prognosis of those who had it usually wasn’t good.
Many individuals were committed to institutions for the rest of their lives because of their inability to function in society. But times have changed.
Bipolar disorder is one of the most important psychiatric illnesses because it is fairly common - affecting between 1 and 3 percent of the population - and quite debilitating. So, what about genetic profiling?
Every bit leads to a higher understanding of what works and what needs to be developed further, that is the way our culture has always operated.
